Minimally oxidised LDL as estimated by a new method increase in plasma of type 2 diabetic patients with atherosclerosis or nephropathy

Diabetes and Metabolism

Volumn 22, Issue 1, 1996, Pages 25-30

  Picard, S ^a   Talussot, C ^a   Serusclat, A ^a   Ambrosio, N ^a   Berthezene, F ^a  

^a Hopital de l'Antiquaille   (France)

Author keywords

alanine; atherosclerosis; minimally oxidised LDL; nephropathy; oxidation

Indexed keywords

ALBUMIN; INSULIN; OXIDIZED LOW DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FEMALE; HIGH RISK PATIENT; HUMAN; INSULIN TREATMENT; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; REPRODUCIBILITY; RISK ASSESSMENT; URINARY EXCRETION; BLOOD VESSEL WALL; CARDIOVASCULAR SYSTEM; DRUG OXIDATION; HIGH RISK POPULATION; KIDNEY DISEASE; METHODOLOGY; PROGNOSIS; PROTEINURIA; ARTERIOSCLEROSIS; BLOOD; CASE CONTROL STUDY; DIABETIC ANGIOPATHY; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; SENSITIVITY AND SPECIFICITY;

ADULT; ARTERIOSCLEROSIS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; HUMANS; LIPOPROTEINS, LDL; MIDDLE AGED; OXIDATION-REDUCTION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0029665731     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. American Diabetes Association. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care, 1989, 12, 573-579.
2. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest, 1991, 88, 1785-1792.
3. Baynes JW. Role of oxidative stress in development of complications of diabetes. Diabetes, 1991, 40, 405-412.
4. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest, 1989, 84, 1086-1095.
5. Van Lente F. Free radicals. Clin Chem, 1993, 65, 374R-377R.
6. Henricksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells : recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA, 1981, 78, 6499-6503.
7. Khouw AS, Parthasarathy S, Witztum JL. Radioiodination of low density lipoprotein initiates lipid peroxidation : protection by use of antioxidants. J Lipid Res, 1993, 34, 1483-1496.
8. Picard S, Parthasarathy S, Fruebis J, Witztum JL. Aminoguanidine inhibits the oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA, 1992, 89, 6876-6880.
9. Phillis-Tsimikas A, Parthasarathy S, Picard S, Palinski W, Witztum JL. Aminoguanidine has both pro-oxidant and antioxidant activity toward low density lipoprotein. Arterioscler Thromb Vasc Biol, 1995, 15, 367-376.
10. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem, 1951, 193, 265-275.
11. Kostner GM, Avogaro P, Bittolo-Bon G, Gazzoloto G. The determination of high density lipoproteins in the lipoprotein laboratory : screening methods compared. Clin Chem, 1979, 25, 939-942.
12. Perrot L, Berthezène F. Dosages radioimmunologiques des apolipoprotéines A-I et A-II. Lyon Med. 1981, 20, 441-445.
13. Karlin JB, Juhn DJ, Scanu AM, Rubenstein AH. Measurements of serum apolipoprotein B by radioimmunoassay. Eur J Clin Invest, 1978, 8, 19-26.
14. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med, 1991, 11, 81-128.
15. Esterbauer H, Jürgens G. Mechanistic and genetic aspects of susceptibility of LDL to oxidation. Curr Opin Lipid, 1993, 4, 114-124.
16. Poli A, Tremoli E, Colombo A, Sirtori M, Pignoli P, Paoletti R. Ultrasonographic measurement of the common artery wall thickness in hypercholesterolemic patients : a new model for the quantitation and follow-up of preclinical atherosclerosis in living human subjects. Atherosclerosis, 1988, 70, 253-261.
17. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science, 1986, 232, 1629-1632.
18. Kalant N, McCormick S, Parniak MA. Effects of copper and histidine on oxidative modification of low density lipoprotein and its subsequent binding to collagen. Arterioscler Thromb, 1991, 11, 1322-1329.
19. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation, 1993, 87 (Suppl. II), II56-II65.
20. Steinberg D. Clinical trials of antioxidants in atherosclerosis : are we doing the right thing ? Lancet, 1995, 346, 36-48.
21. Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J. A prospective study of microalbuminaria as a predictor of mortality in NIDDM. Diabetes Care, 1993, 16, 996-1003.
22. Wasserman J, Santiago A, Rifici V, Holthofer H, Scharschmidt L, Epstein M, Schlondorff D. Interactions of low density lipoprotein with rat mesangial cells. Kidney Int. 1989, 35, 1168-1174.
23. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glucation products : a mechanism for accelerated atherogenesis in diabetes. Biochim Biophys Res Comm, 1990, 173, 932-939.
24. Hicks M, Delbridge L, Yue DK, Reeve TS. Increase in crosslinking of non-enzymatically glycosylated collagen induced by products of lipid peroxidation. Arch Biochem Biophys. 1989, 268, 249-254.
25. Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics) II : associated risk factors. Diabetologia, 1990, 33, 542-548.